Carl Figdor (coordinator), Dept. of Tumor Immunology, theme Cancer development en immune defence received a novel EU 2020 grant named PRECIOUS to develop biodegradable nanomedicines for multimodal precision cancer immunotherapy. In this five year program (8.3 Million Euro’s) the team will produce nanoparticles filled with compounds that manipulate the immune system and test these in the clinic.
For this purpose large scale GMP production will be set up. This will be the first time that advanced nanomedicines that contain multiple active components affecting the immune system will be evaluated in the clinic to treat cancer patients.
<< back to overview news items